10 Best Cancer Stocks to Buy According to Hedge Funds

2. Danaher Corporation (NYSE:DHR)

Number of Hedge Fund Holders: 98

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, industrial, medical, and commercial products and services. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions. The company offers various services in the oncology sector, including gynecology, hematology, radiation, and urology oncology.

The company generated $5.3 billion of free cash flow in fiscal 2024, which resulted in a free cash flow to net income conversion ratio of around 135%. This makes strong free cash flow generation a competitive point for the company. Danaher Corporation (NYSE:DHR) is also active in the M&A domain, completing several strategic acquisitions throughout fiscal 2024 that brought innovative solutions to the company.

Danaher Corporation’s (NYSE:DHR) focus on high-margin bioprocessing in its life sciences sector is another central force in its growth strategy. The anticipated recovery in bioprocessing is expected to significantly increase earnings per share (EPS) for the company in the coming years. The company takes the second spot on our list of the 10 best cancer stocks to buy according to hedge funds.